Jin Peng, Ji Xiaoyan, Tian Yantao
Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Beijing 100021, China.
Department of Emergency Ward, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China.
Clin Res Hepatol Gastroenterol. 2020 Oct;44(5):638-645. doi: 10.1016/j.clinre.2020.02.003. Epub 2020 Mar 5.
A distinctive subset of metastatic gastric cancer (MGC) is oligometastatic disease (OMD), which is characterized by metastatic lesions limited in number and location. Although growing evidence mainly based on retrospective analysis or single center case series has shown favorable prognosis in the management of OMD in gastric cancer with aggressive local treatment, no existing guidelines explicitely address the definition of OMD and there are still controversial opinions on how to proceed in a new era with more effective systemic therapy selection. In this review, we present the current advances and evidence as well as controversial on the management of OMD in MGC, including the definition, diagnosis, local aggressive treatments especially surgery, prognostic factors, current ongoing randomized clinical studied as well as challenges facing the field.
转移性胃癌（MGC）的一个独特亚组是寡转移疾病（OMD），其特征是转移病灶的数量和位置有限。尽管越来越多主要基于回顾性分析或单中心病例系列的证据表明，对OMD进行积极的局部治疗，胃癌的管理预后良好，但现有指南并未明确OMD的定义，对于在新时代如何选择更有效的全身治疗仍存在争议。在本综述中，我们介绍了MGC中OMD管理方面的当前进展、证据以及争议，包括定义、诊断、积极的局部治疗（尤其是手术）、预后因素、当前正在进行的随机临床研究以及该领域面临的挑战。
